Source/Disclosures
Disclosures: Brazzell reports he is an employee of Kala Pharmaceuticals. Please see the study for all other authors' relevant financial disclosures.
September 24, 2020
1 min read
Save

KPI-121 0.25% safe, well-tolerated in patients with dry eye disease

Source/Disclosures
Disclosures: Brazzell reports he is an employee of Kala Pharmaceuticals. Please see the study for all other authors' relevant financial disclosures.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The results of four randomized, double-masked, vehicle-controlled trials showed KPI-121 0.25% is safe and well tolerated with no unexpected treatment-related adverse events in patients with dry eye disease, according to a study.

“The clinical development program for KPI-121 0.25%, which will be marketed as Eysuvis if approved, is the largest to date for a dry eye product. In over 2,800 patients across the four trials, KPI-121 0.25% administered up to 28 days appeared safe and well tolerated with no unexpected adverse events,” Kim Brazzell, PhD, chief medical officer for Kala Pharmaceuticals, told Healio/OSN.

Researchers evaluated the safety results of KPI-121 0.25% (Kala Pharmaceuticals), an ophthalmic nanoparticle suspension of loteprednol etabonate, in patients with dry eye disease in one phase 2 and three phase 3 randomized trials. The trials included 1,430 patients who received KPI-121 four times a day for 2 weeks or longer compared with 1,438 subjects who received vehicle drops.

Adverse events were reported by 12.9% of participants receiving KPI-121 compared with 10.4% of participants receiving vehicle drops. The most reported adverse event was instillation site pain, reported by 5.2% of participants receiving KPI-121 and 4.4% of participants receiving vehicle drops.

In the four trials, 0.5% of KPI-121 participants reported serious adverse events and 0.1% of vehicle drop participants reported serious adverse events.

In addition, 0.6% of KPI-121 participants experienced an IOP elevation, defined as an increase from baseline of greater than 5 mm Hg that resulted in an IOP of 21 mm Hg or higher, compared with 0.2% of vehicle drop participants.

“We believe the excellent safety and tolerability of Eysuvis will resonate well with the medical community for the short-term treatment of the signs and symptoms of dry eye disease,” Brazzell said.